nodes	percent_of_prediction	percent_of_DWPC	metapath
Linezolid—MAOA—attention deficit hyperactivity disorder	0.853	1	CbGaD
Linezolid—MAOB—Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB—MAOA—attention deficit hyperactivity disorder	0.0177	0.162	CbGpPWpGaD
Linezolid—MAOA—locus ceruleus—attention deficit hyperactivity disorder	0.0171	0.453	CbGeAlD
Linezolid—MAOA—Enzymatic degradation of Dopamine by monoamine oxidase—COMT—attention deficit hyperactivity disorder	0.0112	0.102	CbGpPWpGaD
Linezolid—MAOB—Amine Oxidase reactions—MAOA—attention deficit hyperactivity disorder	0.0102	0.093	CbGpPWpGaD
Linezolid—MAOA—Clearance of dopamine—SLC6A3—attention deficit hyperactivity disorder	0.00953	0.087	CbGpPWpGaD
Linezolid—MAOA—Clearance of dopamine—COMT—attention deficit hyperactivity disorder	0.00811	0.074	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—STUB1—attention deficit hyperactivity disorder	0.00555	0.0507	CbGpPWpGaD
Linezolid—MAOA—Serotonin Transporter Activity—TPH2—attention deficit hyperactivity disorder	0.00473	0.0432	CbGpPWpGaD
Linezolid—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—attention deficit hyperactivity disorder	0.00435	0.0397	CbGpPWpGaD
Linezolid—MAOB—Dopamine metabolism—COMT—attention deficit hyperactivity disorder	0.004	0.0365	CbGpPWpGaD
Linezolid—MAOB—Dopamine metabolism—MAOA—attention deficit hyperactivity disorder	0.00397	0.0362	CbGpPWpGaD
Linezolid—MAOA—Serotonin Transporter Activity—SLC6A4—attention deficit hyperactivity disorder	0.00378	0.0345	CbGpPWpGaD
Linezolid—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—COMT—attention deficit hyperactivity disorder	0.0037	0.0338	CbGpPWpGaD
Linezolid—MAOA—Norepinephrine Neurotransmitter Release Cycle—SNAP25—attention deficit hyperactivity disorder	0.00255	0.0233	CbGpPWpGaD
Linezolid—MAOA—Dopamine metabolism—COMT—attention deficit hyperactivity disorder	0.00251	0.0229	CbGpPWpGaD
Linezolid—MAOB—forebrain—attention deficit hyperactivity disorder	0.00248	0.0657	CbGeAlD
Linezolid—MAOB—Alpha-synuclein signaling—SLC6A3—attention deficit hyperactivity disorder	0.00235	0.0214	CbGpPWpGaD
Linezolid—MAOA—Biogenic Amine Synthesis—COMT—attention deficit hyperactivity disorder	0.00224	0.0204	CbGpPWpGaD
Linezolid—MAOA—forebrain—attention deficit hyperactivity disorder	0.00212	0.056	CbGeAlD
Linezolid—MAOB—cardiovascular system—attention deficit hyperactivity disorder	0.0021	0.0555	CbGeAlD
Linezolid—MAOA—cardiovascular system—attention deficit hyperactivity disorder	0.00179	0.0474	CbGeAlD
Linezolid—MAOB—midbrain—attention deficit hyperactivity disorder	0.00164	0.0434	CbGeAlD
Linezolid—MAOA—midbrain—attention deficit hyperactivity disorder	0.0014	0.037	CbGeAlD
Linezolid—MAOB—nervous system—attention deficit hyperactivity disorder	0.00135	0.0357	CbGeAlD
Linezolid—MAOB—central nervous system—attention deficit hyperactivity disorder	0.0013	0.0343	CbGeAlD
Linezolid—MAOA—Neurotransmitter Release Cycle—SNAP25—attention deficit hyperactivity disorder	0.0013	0.0118	CbGpPWpGaD
Linezolid—MAOB—cerebellum—attention deficit hyperactivity disorder	0.00127	0.0336	CbGeAlD
Linezolid—MAOA—nervous system—attention deficit hyperactivity disorder	0.00115	0.0304	CbGeAlD
Linezolid—MAOA—central nervous system—attention deficit hyperactivity disorder	0.00111	0.0293	CbGeAlD
Linezolid—MAOA—cerebellum—attention deficit hyperactivity disorder	0.00108	0.0286	CbGeAlD
Linezolid—MAOB—brain—attention deficit hyperactivity disorder	0.00103	0.0273	CbGeAlD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000947	0.00864	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.000908	0.00829	CbGpPWpGaD
Linezolid—MAOA—brain—attention deficit hyperactivity disorder	0.000878	0.0233	CbGeAlD
Linezolid—MAOA—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.000696	0.00635	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.000567	0.00518	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000506	0.00462	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000503	0.00459	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.000488	0.00445	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000465	0.00424	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.000453	0.00414	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.000453	0.00414	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.0004	0.00365	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000372	0.00339	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000356	0.00325	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000331	0.00302	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000329	0.003	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000318	0.0029	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000306	0.0028	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000285	0.0026	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000282	0.00257	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000278	0.00254	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000254	0.00232	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000216	0.00197	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000207	0.00189	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000147	0.00134	CbGpPWpGaD
Linezolid—MAOB—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000143	0.0013	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000143	0.0013	CbGpPWpGaD
Linezolid—MAOB—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000141	0.00128	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000131	0.00119	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00013	0.00119	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000114	0.00104	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000109	0.000993	CbGpPWpGaD
Linezolid—MAOA—Metabolism—TPH2—attention deficit hyperactivity disorder	8.97e-05	0.000819	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.97e-05	0.000819	CbGpPWpGaD
Linezolid—MAOA—Metabolism—DPYD—attention deficit hyperactivity disorder	8.82e-05	0.000805	CbGpPWpGaD
Linezolid—MAOB—Metabolism—COMT—attention deficit hyperactivity disorder	8.66e-05	0.00079	CbGpPWpGaD
Linezolid—MAOB—Metabolism—MAOA—attention deficit hyperactivity disorder	8.6e-05	0.000785	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.2e-05	0.000749	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.17e-05	0.000654	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.83e-05	0.000623	CbGpPWpGaD
Linezolid—MAOA—Metabolism—COMT—attention deficit hyperactivity disorder	5.43e-05	0.000496	CbGpPWpGaD
Linezolid—MAOB—Metabolism—EP300—attention deficit hyperactivity disorder	3.71e-05	0.000339	CbGpPWpGaD
Linezolid—MAOA—Metabolism—EP300—attention deficit hyperactivity disorder	2.33e-05	0.000213	CbGpPWpGaD
